| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
The target of 4-Methylumbelliferyl-β-D-xylopyranoside is the enzyme β-xylosidase, which catalyzes the hydrolysis of xylosidic bonds. Its mechanism of action is as a substrate for this enzyme. When β-xylosidase cleaves the glycosidic bond between the xylose sugar and the 4-methylumbelliferone moiety, the latter is released. 4-Methylumbelliferone is highly fluorescent under alkaline conditions. This enzymatic reaction converts a non-fluorescent or weakly fluorescent substrate into a highly fluorescent product, enabling the sensitive and quantitative measurement of β-xylosidase activity.
|
|---|---|
| ln Vitro |
In vitro, 4-Methylumbelliferyl-β-D-xylopyranoside is used as a substrate for studying β-xylosidase activity. It displays bursting steady-state kinetics, supporting the conclusion that the substrate undergoes rapid hydrolysis of the glycosidic bond. The compound is a fluorogenic substrate, meaning that the product of the enzymatic reaction is fluorescent, allowing for real-time monitoring of enzyme activity. It is used in enzyme kinetics studies to determine the kinetic parameters (Km, Vmax) of β-xylosidases and to screen for inhibitors of this enzyme.
|
| ln Vivo |
In vivo activity of 4-Methylumbelliferyl-β-D-xylopyranoside is not typically studied, as it is a substrate for in vitro enzyme assays. However, β-xylosidase activity is present in various organisms, including fungi, bacteria, and plants. The substrate could potentially be used to measure β-xylosidase activity in biological samples or to study the role of this enzyme in vivo. Its use would be limited to research applications, as it is not a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays using 4-Methylumbelliferyl-β-D-xylopyranoside are based on its role as a fluorogenic substrate for β-xylosidase. A standard protocol: the substrate is dissolved in an appropriate buffer (e.g., citrate buffer, pH 4.5-5.5). The enzyme (β-xylosidase) is added to the substrate solution in a 96-well plate. The reaction mixture is incubated at 37°C for a defined period (e.g., 15-60 minutes). The reaction is stopped by the addition of a stop solution (e.g., glycine-NaOH buffer, pH 10.0), which also enhances the fluorescence of the released 4-methylumbelliferone. The fluorescence is measured using a fluorometer with excitation at 365 nm and emission at 450 nm.
|
| Cell Assay |
In vitro cell-based assays using 4-Methylumbelliferyl-β-D-xylopyranoside are not common, as it is primarily a cell-free enzyme substrate. However, it could be used to measure β-xylosidase activity in cell lysates or to assess the activity of secreted β-xylosidases from cultured cells. A standard protocol: cells are cultured and lysed, or the culture supernatant is collected. The sample is incubated with the substrate in a buffer at an appropriate pH. The fluorescence of the released 4-methylumbelliferone is measured over time. This assay can be used to compare β-xylosidase activity between different cell types or under different experimental conditions.
|
| Animal Protocol |
In vivo animal experiments using 4-Methylumbelliferyl-β-D-xylopyranoside are not typically performed, as it is a substrate for in vitro assays. However, it could potentially be used to measure β-xylosidase activity in tissues or biological fluids. For example, the substrate could be injected into an animal, and the appearance of fluorescent 4-methylumbelliferone in the blood or urine could be monitored. This would provide a measure of systemic β-xylosidase activity. Such applications are more common for research on enzyme deficiencies or for drug development.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-Methylumbelliferyl-β-D-xylopyranoside are not a primary focus of study. As a substrate for in vitro assays, its stability in solution and its solubility are the main considerations. The compound is typically stored as a powder at -20°C and is soluble in DMSO and aqueous buffers. Its molecular weight is 308.28 g/mol. Once cleaved by β-xylosidase, the released 4-methylumbelliferone is a small lipophilic molecule that can be absorbed and metabolized.
|
| Toxicity/Toxicokinetics |
Toxicity data for 4-Methylumbelliferyl-β-D-xylopyranoside is limited. As a fluorogenic substrate, it is generally considered to have low toxicity at the concentrations used for enzyme assays (typically in the micromolar to millimolar range). The released product, 4-methylumbelliferone, is also considered to have low toxicity. However, standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
4-Methylumbelliferyl-β-D-xylopyranoside (MuX) is a fluorogenic substrate for β-xylosidase activity studies. It displays bursting steady-state kinetics, indicating rapid hydrolysis of the glycosidic bond. The compound is used as a substrate for the research of β-xylosidase activity. It is not a drug and has no clinical use or approval status. It is commercially available from chemical suppliers for research purposes only.
|
| Molecular Formula |
C15H16O7
|
|---|---|
| Molecular Weight |
308.2833
|
| Exact Mass |
308.089
|
| CAS # |
6734-33-4
|
| PubChem CID |
92229
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
572.1±50.0 °C at 760 mmHg
|
| Melting Point |
223ºC
|
| Flash Point |
217.3±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.647
|
| LogP |
1.02
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
463
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H](CO3)O)O)O
|
| InChi Key |
JWIYLOHVJDJZOQ-KAOXEZKKSA-N
|
| InChi Code |
InChI=1S/C15H16O7/c1-7-4-12(17)22-11-5-8(2-3-9(7)11)21-15-14(19)13(18)10(16)6-20-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15+/m1/s1
|
| Chemical Name |
4-methyl-7-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxychromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~405.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2438 mL | 16.2190 mL | 32.4380 mL | |
| 5 mM | 0.6488 mL | 3.2438 mL | 6.4876 mL | |
| 10 mM | 0.3244 mL | 1.6219 mL | 3.2438 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
